MIRA
INFORM REPORT
|
Report Date : |
28.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
SANOFI-AVENTIS DE MEXICO S.A. DE C.V. |
|
|
|
|
Registered Office : |
Av. Universidad Nº1738,
Col. Coyoacan, Del. Coyoacan, Mexico DF, CP 0400 |
|
|
|
|
Country : |
Mexico |
|
|
|
|
Date of Incorporation : |
21.05.1957 |
|
|
|
|
Legal Form : |
Stock Company of
Variable Capital |
|
|
|
|
Line of Business : |
Engaged in the
production and distribution of pharmaceutical products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
IDENTIFICATION
CORRECT COMPANY NAME : SANOFI-AVENTIS DE MEXICO
S.A. DE C.V.
TRADE NAME :
"SANOFI AVENTIS DE MEXICO "
TAXPAYER REGISTRATION : RFC SAM951123978
OPERATING STATUS :
Active
MAIN ADDRESS :
Av. Universidad Nº1738, Col. Coyoacan, Del.
Coyoacan
CITY/PROVINCE/STATE :
Mexico DF, CP 0400
COUNTRY : MEXICO
TELEPHONE :
(5255)5484.4400
FAX : (5255)5484.4969
WEB SITE : www.aventis.com.mx
COMMENTS -
Free call : 01 800 123 41
41
SUMMARY
Incorporation
: 1957
Operating Status :
Active
Shareholders' Equity : 60,764,167,000.=
Annual Sales
: 38,934,327,000.00 US$ Dollars
Employees
: 2,500
QUALIFICATION
RATING : ELIGIBLE FOR MODERATE CREDITS
PAYMENTS : PAYMENTS USUALLY PROMPT
LEGAL BACKGROUNDS
LEGAL STATUS :
Stock Company of Variable Capital
DATE OF INCORPORATION : 21MAY1957
REGISTERED IN :
Mexico DF
DURATION : 99 years
SHAREHOLDERS' EQUITY : US$60,764,167,000 (31/12/2006-Consolidated)
CURRENT EXCHANGE RATE : Ps$10.82 per USD1
COMMENTS -
Subject is a member of
the National Chamber of the Pharmaceutical Industry - CANIFARMA.
DIRECTORS / EXECUTIVES / SHAREHOLDERS
FULL NAMES / COMPANY NAME TITLE OWNERSHIP %
CARTIER, NICOLAS Director General
MENDOZA ROCHA,
FRANCISCO Corpor. Affairs
Director
JACOME RODRIGUEZ,
FELIPA Purchase Manager
SANOFI AVENTIS S.A. Shareholder Maj.Shareh
WHO IS WHO ?
CARTIER,
NICOLAS
MENDOZA
ROCHA, FRANCISCO
JACOME
RODRIGUEZ, FELIPA
SANOFI
AVENTIS S.A.
It is the world leader in
the pharmaceutical industry, the First in Europe and the Second one in
Mexico. Operating in over a hundred
countries, Sanofi-Aventis markets major pharmaceutical products derived from
its research and a very wide range of medicines adapted to local needs
throughout the world. It has more than 80 industrial plants and about 100,000
employees globally.
This Company operates
seven major therapeutic areas : Cardiovascular, thrombosis, metabolic
disorders, oncology, central nervous system, internal medicine and vaccines.
Furthermore, its shares are listed in the Stock Exchange Market of Paris
(EURONEXT: SAN) and New York (NYSE)
It has more than 20
research centers in three continents.
Annual budget totals a
little more than 4 Billion Euros, one of the three more important ones in the
pharmaceutical industry worlwide.
SANOVI-AVENTIS S.A. has one
of the most complete and innovative portfolios of the industry.
Corporate Offices: 174 Avenue de France, Paris 75013
Tel. 331 53 77 45 45
RELATED COMPANY(IES)
Subject is a part of the
corporation SANOFI AVENTIS S.A., a world leading company in the pharmaceutical
industry, Number 1 in Europe.
COMPANY NAME COUNTRY RELATION
SANOFI AVENTIS S.A. FRANCE Parent
Co.
BUSINESS
MAIN ACTIVITY .-
Subject is engaged in the
production and distribution of pharmaceutical products. For this purpose it has
seven major therapeutic areas: Cardiovascular, thrombosis, diabetes, oncology,
central nervous system, internal medicine and vaccines.
Trademarks: LOVENOX®;
CLEXANE®; PLAVIX®; STILNOX®; AMBIEN®; MYSLEE®; TAXOTERE®; ELOXATINE®; LANTUS®;
COPAXONE®; APROVEL®; AVAPRO®; KARVEA®; TRITACE®; DELIX®; ALTACE®; ALLEGRA®;
TELFAST®; AMARYL®; AMAREL®; SOLOSA®; XATRAL®; ACTONEL®; DEPAKINE®
IMPORT : Yes United States, Italy, Brazil; direct credit at
30 days
EXPORT : Yes Central American countries; direct credit at 30
days
% CASH SALES/METHOD :
10%
% CREDIT SALES/TERMS :
90%
% FOREIGN SALES(COUNTRIES) : 15%
% DOMESTIC PURCHASES :
80%
% FOREIGN PURCHASES :
20%
SELLING TERRITORY :
85% - domestic market
EMPLOYEES :
About 2,500 (1,500 sellers)
FACILITIES –
Condition : Premises situated in a urban commercial area of the city
Use
: Registered offices, corporate offices
Remarks
and other Premises .-
Production Plants and
Distribution Centers. State of Mexico (Cuautitlan and Ocoyoacac)
One of them situated at:
Acueducto del Alto Lerma
Nº2, Pueblo Ocoyoacac, Coyoacac, Estado de Mexico, CP 52740.
This plant was awarded
the prize "Clean Industry" and "Safe Industry"
COMMENTS -
SANOFI-AVENTIS DE MEXICO
S.A. DE C.V. is present in Mexico through its medicines, medical
representatives, research and development of new products, manufacturing plants
and distribution centers.
CLIENTS. Subject sells
products through distributors directly to the Public Health Sector, among them:
- CASA SABA S.A. DE C.V.
- NADRO S.A. DE C.V.
- IMSSS
- ISSTE
FINANCIAL INFORMATION
All the information contained
in this report has been collected from different outside sources as it was not
possible to get information directly from Subject Company.
Thus, through such
sources we could access to the CONSOLIDATE BALANCE SHEET OF SANOFI-AVENTIS and
SUBSIDIARIES for the Fiscal Year ended as of December 31, 2006, expressed in
US$ Dollars as follows:
BALANCE
SHEET DATE : 31DEC2006
TYPE OF
BALANCE SHEET : Consolidated
BALANCE
SHEET OF : 12
months
CURRENCY : US$ Dollars
ASSETS
TOTAL
CURRENT : 18,106,594,000.00
FIXED : 77,187,379,000.00
OTHERS : 7,076,808,000.00
TOTAL
ASSETS : 102,370,781,000.00
LIABILITIES
TOTAL
CURRENT : 13,522,513,000.00
LONG TERM :
28,084,101,000.00
TOTAL
EQUITY : 60,764,167,000.00
TOTAL
LIABILITIES : 102,370,781,000.00
SALES : 38,934,327,000.00
PROFIT (LOSS) : 5,326,090,000.00
LIQUIDITY RATIO : 1.34
(Current Assets/Current Liabilities)
DEBT-TO-EQUITY
RATIO: 449.36% (Shareholders'equity/Current Liabilities)
PROFITABILITY MARGIN: 13.68%
(Profits/Sales)
WORKING CAPITAL :
4,584,081,000.00 (Current
Assets - Current Liabilities)
PROPERTIES OF THE COMPANY -
Main assets include:
- Furniture and fixtures
- Computer equipment
- Vehicles
- Machinery and equipment
- Laboratories
PAYMENTS RECORD
TRADE REFERENCES –
Monthly
Average Terms(days)) Performance?
Time Products/Services Supplier
1 Ps$ 900,000 30 days Prompt Sv.yrs. Raw material Domestic
2 Ps$ 800,000 30 days Prompt Sv.yrs. Raw material Domestic
3 Ps$ 700,000 30 days Prompt Sv.yrs. Jelly capsules Domestic
4 Ps$ 650,000 30 days Prompt Sv.yrs. Vials Domestic
5 Ps$ 450,000 30 days Prompt Sv.yrs. Labels Domestic
LIST OF DOMESTIC SUPPLIERS -
Suppliers
listed Alphabetically. There is not
relationship as for the order above
Supplier _
CAPSUGEL DE MEXICO S. DE
R. L. DE C.V.
FORMA VITRUM DE MEXICO
S.A. DE C.V.
FORMIL
HELM DE MEXICO S.A.
IPCA LABORATORIES
LIMITED
LA ETIQUETA S.A. DE
C.V.
PRODUCTOS ROCHE S.A. DE
C.V.
SPI PHARMACEUTICALS
BANKING INFORMATION
BANKERS
Bank
BANCO NACIONAL DE MEXICO
S.A.
BBVA BANCOMER S.A.
Subject is a client of
the above banks. Additional information was not disclosed.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)